Related Experiment Videos
Potentiation of neuromuscular weakness in infant botulism by aminoglycosides
Abstract:
A retrospective study of ten patients with infant botulism who received gentamicin or kanamycin suggests that aminoglycoside antibiotics potentiate muscular weakness and precipitate respiratory failure as late as 27 days after onset of the disease. Although it is difficult to separate progression of the disease from the effects of antibiotics, the rapidity of deterioration following aminoglycoside treatment and the rapidity of recovery following cessation of aminoglycoside therapy is highly suggestive. A review of five patients who received only penicillin or a semisynthetic derivative of penicillin did not reveal any temporal deterioration with onset of penicillin therapy or improvement with cessation of penicillin therapy.
Insights
Aminoglycoside antibiotics like gentamicin may worsen infant botulism symptoms, including muscle weakness and respiratory failure. Stopping these drugs appears to improve patient recovery, suggesting a link between aminoglycosides and disease progression.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Neuromuscular Disorders
Background:
- Infant botulism is a serious condition caused by Clostridium botulinum toxin.
- Treatment often involves supportive care and, historically, antibiotics.
- The potential impact of specific antibiotics on disease course requires investigation.
Observation:
- A retrospective review examined ten infant botulism cases treated with aminoglycoside antibiotics (gentamicin or kanamycin).
- Five additional cases treated with penicillin or penicillin derivatives were also reviewed.
- Clinical data focused on the temporal relationship between antibiotic administration and disease progression/resolution.
Findings:
- Aminoglycoside antibiotics (gentamicin, kanamycin) were associated with potentiated muscular weakness and respiratory failure in infant botulism patients.
- Deterioration occurred as late as 27 days post-onset, with rapid improvement following aminoglycoside cessation.
- No similar temporal deterioration or improvement was observed in patients treated solely with penicillin.
Implications:
- Aminoglycoside use in infant botulism warrants caution due to potential exacerbation of neuromuscular weakness.
- Discontinuation of aminoglycosides may be beneficial for patients experiencing unexplained clinical deterioration.
- Further research is needed to elucidate the precise mechanisms of aminoglycoside-induced potentiation of botulism symptoms.